Novo Holdings Invests in Oxford Biomedica plc

Novo Holdings Invests £50m in Oxford Nanopore Technologies

August 1, 2024

Biotechnology

Novo Holdings has invested £50 million in UK-listed Oxford Nanopore Technologies via an equity issue and intends to make further share purchases in the secondary market. The investment is intended to support Oxford Nanopore's commercial growth and capability expansion in biopharmaceutical and biomanufacturing markets.

Novo Holdings Leads $50M Growth Investment in MedGenome

August 30, 2022

Biotechnology

Novo Holdings led a $50 million minority investment in MedGenome alongside existing investors LeapFrog Investments and Sofina. The capital will support MedGenome’s expansion beyond South Asia into Africa and the Middle East and broaden access to its genomic testing, bioinformatics and research services.

Novo Holdings Acquires Medical Knowledge Group

January 3, 2022

Healthcare Services

Novo Holdings A/S has agreed to acquire Medical Knowledge Group (MKG) from Court Square Capital and Aisling Capital. MKG is an analytics-driven, technology-enabled drug commercialisation and medical communications platform headquartered in New York with more than 500 employees; Novo said the acquisition will support MKG's continued growth in biopharmaceutical commercialisation services.

Novo Holdings Acquires BBI Group

June 15, 2021

Medical Devices

Novo Holdings A/S has agreed to acquire BBI Group from Exponent for an enterprise value of over GBP 400 million, becoming the company's majority shareholder. BBI, a Crumlin, South Wales–headquartered supplier of diagnostics reagents, lateral flow development and diagnostic manufacturing services with more than 400 employees, will benefit from Novo Holdings' life-sciences expertise to pursue organic and inorganic growth.

Novo Holdings Acquires Double-Digit Stake in bioMASON

December 17, 2019

Manufacturing

Novo Holdings A/S made a multimillion-dollar, double-digit equity investment in US-based bioMASON to help commercialize its bacteria-grown biocement masonry products. As part of the deal Anders Spohr of Novo Holdings will join bioMASON's board as the company scales its sustainable concrete alternative for construction and infrastructure markets.

Novo Holdings Invests $72 Million in LanzaTech

August 6, 2019

Biotechnology

Novo Holdings A/S made a $72 million Series E growth equity investment in LanzaTech to support expansion and commercialization of the company's carbon-recycling fuels and chemicals platform. Anders Bendsen Spohr of Novo Holdings will join LanzaTech's board as the investment aims to accelerate deployment of LanzaTech's sustainable fuels, chemicals and polyethylene produced from recycled carbon.